RESUMO
Changes in the glycosylation process appear early in carcinogenesis and evolve with the growth and spread of cancer. The correlation of the characteristic glycosylation signature with the tumor stage and the appropriate therapy choice is an important issue in translational medicine. Oncologists also pay attention to extracellular vesicles as reservoirs of new cancer glycomarkers that can be potent for cancer diagnosis/prognosis. In this review, we recall glycomarkers used in oncology and show their new glycoforms of improved clinical relevance. We summarize current knowledge on the biological functions of glycoepitopes in cancer-derived extracellular vesicles and their potential use in clinical practice. Is glycomics a future of cancer diagnosis? It may be, but in combination with other omics analyses than alone.
Assuntos
Vesículas Extracelulares , Neoplasias , Humanos , Glicosilação , Neoplasias/diagnóstico , Neoplasias/terapia , Neoplasias/metabolismo , Carcinogênese/metabolismo , Vesículas Extracelulares/metabolismo , GlicômicaRESUMO
Changes in glycosylation pattern of cell surface, body fluids and extracellular matrix glycoconjugates is a characteristic feature of tumor cell malignancy. These changes are the result of mutations of tumor-associated genes as well as epigenetic changes in the tumor environment, including nutrient influx, hypoxia, cytokine expression and stimulation of chronic inflammation. The unique set of cell surface glycoantigens on neoplastic cells is recognized by endogenous lectins located in the extracellular matrix, vascular endothelium, on leukocytes or platelets, and has an impact on disrupting basic cellular processes, such as intercellular recognition, cell-cell adhesion or cell-ECM interaction. These changes have a critical impact on the migration, invasive and metastatic potential of neoplastic cells and modulate the immune response. This unique pattern of sugar antigens on the cancer cells can be a vaulable marker to identify them, determine the stage of the disease as well as be a target of anti-cancer therapy.